[go: up one dir, main page]

WO2003035619A8 - Tyrosine kinase inhibitors - Google Patents

Tyrosine kinase inhibitors

Info

Publication number
WO2003035619A8
WO2003035619A8 PCT/US2002/033962 US0233962W WO03035619A8 WO 2003035619 A8 WO2003035619 A8 WO 2003035619A8 US 0233962 W US0233962 W US 0233962W WO 03035619 A8 WO03035619 A8 WO 03035619A8
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
tyrosine kinase
kinase inhibitors
present
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/033962
Other languages
French (fr)
Other versions
WO2003035619A1 (en
Inventor
B Wesley Trotter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of WO2003035619A1 publication Critical patent/WO2003035619A1/en
Publication of WO2003035619A8 publication Critical patent/WO2003035619A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises a 2-carboxamidopyrrole. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.
PCT/US2002/033962 2001-10-25 2002-10-21 Tyrosine kinase inhibitors Ceased WO2003035619A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34300001P 2001-10-25 2001-10-25
US60/343,000 2001-10-25

Publications (2)

Publication Number Publication Date
WO2003035619A1 WO2003035619A1 (en) 2003-05-01
WO2003035619A8 true WO2003035619A8 (en) 2003-07-03

Family

ID=23344243

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/033962 Ceased WO2003035619A1 (en) 2001-10-25 2002-10-21 Tyrosine kinase inhibitors

Country Status (1)

Country Link
WO (1) WO2003035619A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946278B2 (en) 2007-02-07 2015-02-03 Glaxosmithkline Llc Inhibitors of AkT activity

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2372363A1 (en) 2005-09-20 2011-10-05 OSI Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1
EP2400985A2 (en) 2009-02-25 2012-01-04 OSI Pharmaceuticals, LLC Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
JP2012519170A (en) 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー INSITU method for monitoring EMT status of tumor cells in vivo
JP2012519281A (en) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー Methods for identifying mesenchymal tumor cells or agents that inhibit their production
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
AU2011223643A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
JP2013520998A (en) 2010-03-03 2013-06-10 オーエスアイ・ファーマシューティカルズ，エルエルシー Biological markers useful for predicting anticancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011112666A1 (en) 2010-03-09 2011-09-15 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
EP2702173A1 (en) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
JP6255038B2 (en) 2013-02-26 2017-12-27 トリアクト セラピューティクス，インク． Cancer treatment
US9381246B2 (en) 2013-09-09 2016-07-05 Triact Therapeutics, Inc. Cancer therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1139754A4 (en) * 1998-12-31 2002-12-18 Sugen Inc 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946278B2 (en) 2007-02-07 2015-02-03 Glaxosmithkline Llc Inhibitors of AkT activity

Also Published As

Publication number Publication date
WO2003035619A1 (en) 2003-05-01

Similar Documents

Publication Publication Date Title
WO2004014300A3 (en) Tyrosine kinase inhibitors
WO2004014851A3 (en) Tyrosine kinase inhibitors
WO2003035615A3 (en) Tyrosine kinase inhibitors
WO2003035616A3 (en) Tyrosine kinase inhibitors
WO2003035619A8 (en) Tyrosine kinase inhibitors
WO2003035614A3 (en) Tyrosine kinase inhibitors
WO2004031401A3 (en) Novel tyrosine kinases inhibitors
WO2002046183A3 (en) Indazolyl-substituted pyrroline compounds as kinase inhibitors
AU2001241798A1 (en) 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors
WO2004096795A3 (en) C-fms kinase inhibitors
WO2000043373A3 (en) Kinase inhibitors
WO2001019828A3 (en) Kinase inhibitors as therapeutic agents
AP1718A (en) 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors
WO2000002576A3 (en) Egf-genistein for prevention of restenosis
EP0766676A4 (en) Compounds for and method of inhibiting phosphodiesterase iv
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
WO2001060814A3 (en) Pyrrole substituted 2-indolinone protein kinase inhibitors
WO2004009597A3 (en) Pyrazolopyrimidines as protein kinase inhibitors
AU2001288374A1 (en) Substituted oxindole derivatives as tyrosine kinase inhibitors
WO2006047503A3 (en) Inhibitors of c-fms kinase
WO2002081728A3 (en) Quinoline inhibitors of hyak1 and hyak3 kinases
WO2001056573A8 (en) Use of cox-2 inhibitors as gastroprokinetics
EP1390052A4 (en) Inhibition of jun kinase
WO2003037863A3 (en) Substituted indoles, method for production and use thereof for the inhibition of pain
WO2003086315A3 (en) Tyrosine kinase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 18/2003 UNDER (22) REPLACE "23 OCTOBER 2002 (23.10.2002)" BY "21 OCTOBER 2002 (21.10.2002)"

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP